PTC
BCAX

Private Trust Company’s Bicara Therapeutics BCAX Stock Holding History

Private Trust Company’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.47K Hold
225
– – ﹤0.01% 2222
2025
Q4 		$3.79K Hold
225
– – ﹤0.01% 2235
2025
Q3 		$3.55K Buy
+225
New +$2.52K ﹤0.01% 2234

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Private Trust Company's BCAX Position: Q1 2026 in Review

Private Trust Company held its Bicara Therapeutics (BCAX) position steady in Q1 2026 at 225 shares worth $4.47K. The position accounts for ﹤0.01% of the portfolio, ranked #2222.

Private Trust Company first reported a position in BCAX in Q3 2025 and has held it in 3 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Private Trust Company held 225 shares of Bicara Therapeutics worth $4.47K as of Q1 2026.
  • Private Trust Company left its Bicara Therapeutics share count unchanged in Q1 2026.
  • Bicara Therapeutics made up ﹤0.01% of Private Trust Company's portfolio in Q1 2026, its #2222 holding.
  • Private Trust Company first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Private Trust Company's 13F filing for Q1 2026, filed 30 Apr 2026.